Sponsor Overview
Explore verified public information about Amgen's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 4 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 2 supporting sources.
“Amgen may provide physician-requested expanded access to its investigational products to patients with serious or immediately life-threatening diseases who lack other therapeutic options, cannot join an active clinical trial of the investigational product, and where the potential benefits of the investigational product are greater than the known risks in the disease indication (as described by the criteria below).”
“In limited circumstances, Amgen provides continued or expanded access to its investigational products, as permitted by applicable law.”
Active EAPs on ClinicalTrials.gov
Score contribution: 60 — 1 supporting sources.
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 10 supporting sources.
Conditions: Thyroid Eye Disease, Graves' Orbitopathy
Conditions: Unresected Stage IIIB to IVM1c Melanoma
Conditions: Non Small-cell Lung Cancer, Locally Advanced Unresectable NSCLC, Locally Advanced Metastatic NSCLC
Conditions: Bechet's Disease
Conditions: Unresected Stage IIIb to IVM1c Melanoma
Reagan-Udall Foundation Insights
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.